Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8757759 | 1.00 | CXCR4 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL169698 | 0.91 | — | — | |
| SCHEMBL169700 | 0.91 | — | — | |
| Methane SCHEMBL27320849 | 0.89 | MAPT (0.37) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL3293047 | 0.89 | SMN1; SMN2 (0.37) | CXCR4ADRA2CHRH3SIGMAR1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL175417 | 0.89 | POLB (0.37) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL5301309 | 0.89 | SMN1; SMN2 (0.37) | CXCR4ADRA2CHRH3SIGMAR1ALDH1A1 | |
| Bromide SCHEMBL27980411 | 0.89 | POLB (0.37) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL8155578 | 0.89 | POLB (0.37) | CXCR4ADRA2CHRH3SIGMAR1ALDH1A1 | |
| SCHEMBL8581174 | 0.89 | CXCR4 (0.40) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | claimed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | claimed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | claimed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | claimed |
| JP-60193985-A | — | — | None | — | — | JP | disclosed |
| EP-3476832-B1 | CATIONIC LIPID | EISAI R&D MAN CO LTD (JP) | 2023-04-19 | — | — | EP | disclosed |
| WO-2020184670-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | 大塚製薬株式会社 | 2020-09-17 | — | — | WO | disclosed |
| US-20190218180-A1 | Cationic Lipid | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-07-18 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| EP-3476832-A1 | CATIONIC LIPID | Eisai R&D Management Co., Ltd. (JP) | 2019-05-01 | — | — | EP | disclosed |
| CN-109311809-A | Cationic lipids | 卫材R&D管理有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| EP-0894800-A2 | Aliphatic solutions of aminoalkyllithium compounds | Bridgestone Corporation (JP) | 1999-02-03 | — | — | EP | disclosed |
| CN-1192729-A | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-09-09 | — | — | CN | disclosed |
| US-5661148-A | ANTIHYPOXIC AGENT FOR RESPIRATORY SYSTEM DISORDER | TEIJIN LIMITED (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0514540-B1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0514540-A1 | PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-11-25 | — | — | EP | disclosed |
| US-4826840-A | 5,6-METHYLENEDIOXYINDENE DERIVATIVES | TAIYO PHARMACEUTICAL INDUSTRY CO., LTD. (JP) | 1989-05-02 | — | — | US | disclosed |
| EP-0283551-A2 | Ameliorant of cerebral circulation and metabolism | Taiyo Pharmaceutical Industry Co., Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| JP-S60193985-A | ENZYME ACTIVITY INHIBITOR | KAKIUCHI SHIRO | 1985-10-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218180-A1 | Cationic Lipid | NPC1L1, NPC1, LPCAT1 | CXCR4 959/4885MEN1 1576/4885CHRM2 2799/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | CXCR4 3638/4885MEN1 13/4885CHRM2 4554/4885 |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | TP53, KRAS, NRAS | CXCR4 2169/4885MEN1 1376/4885CHRM2 4843/4885 |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | CXCR4 2669/4885MEN1 3892/4885CHRM2 2371/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | CXCR4 3038/4885MEN1 63/4885CHRM2 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.